Thermo Fisher Scientific (TMO) shares slide following YoY revenue decline in Q1

Shares of Thermo Fisher Scientific (NYSE: TMO) are down a further 4% premarket Wednesday after reporting a 9% year-on-year revenue decline.

TMO's fall adds to its more than 4% slide in Tuesday's session, closing at $548.38 per share. It is currently trading below the $527 mark.

The company, which supplies scientific instrumentation, reagents and consumables, and software services, reported Q1 EPS of $5.03, in-line with the analyst estimate of $5.03. Revenue for the quarter came in at $10.71 billion versus the consensus estimate of $10.65 billion. The company reported revenue of $11.82 billion during the same period last year.

The YoY decline in revenue was driven by a lackluster performance in its life sciences division which posted revenue of $2.6 billion, down from $4.2 billion in the same period last year. Meanwhile, Covid testing revenue came in at $0.14 billion.

"The team executed very well to navigate a dynamic macroenvironment, enable our customers' success, and drive share gain," said Marc Casper, chairman, president and chief executive officer of Thermo Fisher. "We are incredibly well positioned to deliver differentiated performance, as we continue to create value for all of our stakeholders and build an even brighter future for our company."

By Sam Boughedda

You May Also Be Interested In

• Piper Sandler Starts Thermo Fisher Scientific (TMO) at Neutral
• Adobe earnings preview: Mizuho expects solid beat but sees no re-rating catalyst
• Analyst names this stock the "clear beneficiary" of refined copper tariffs